Wei, L., Lim, S. G., Xie, Q., Văn, K. N., Piratvisuth, T., Huang, Y., Wu, S., Xu, M., Tang, H., Cheng, J., Le Manh, H., Gao, Y., Mou, Z., Sobhonslidsuk, A., Dou, X., Thongsawat, S., Nan, Y., Tan, C. K., Ning, Q., Tee, H. P., Mao, Y., Stamm, L. M., Lu, S., Dvory-Sobol, H., Mo, H., Brainard, D. M., Yang, Y., Dao, L., Wang, G., Tanwandee, T., Hu, P., Tangkijvanich, P., Zhang, L., Gao, Z. L., Lin, F., Le, T. T. P., Shang, J., Gong, G., Li, J., Su, M., Duan, Z., Mohamed, R., Hou, J. L., & Jia, J. (2019). sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet gastroenterology and hepatology, 4, 127–134. http://access.bl.uk/ark:/81055/vdc_100076782065.0x000002